INDIGO
Phase 2 Withdrawn
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 Withdrawn
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
Phase 2 Withdrawn
NEGOTIATE
Phase 2 Withdrawn
Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma
Phase 2 Withdrawn
APPEAL
Phase 2 Withdrawn
AERESA
Phase 2 Withdrawn
Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study
Phase 2 Withdrawn
Re-Induce 2
Phase 2 Withdrawn
SCION
Phase 2 Withdrawn
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
Phase 2 Withdrawn
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
Oral Iloprost for the Prevention of Lung Cancer In Former Smokers
Phase 2 Withdrawn
INTRUSION
Phase 2 Withdrawn
NSCLC
Phase 2 Withdrawn
Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
Phase 2 Withdrawn
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
Phase 2 Withdrawn
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
Phase 2 Withdrawn
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
Phase 2 Withdrawn
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Phase 2 Withdrawn
SABR for T1-2a N1 NSCLC
Phase 2 Withdrawn
Charcoal in Lung Cancer Patients Undergoing TEMLA
Phase 2 Withdrawn
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Phase 2 Withdrawn
A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
Phase 2 Withdrawn
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
Phase 2 Withdrawn
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
Phase 2 Withdrawn
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
Phase 2 Withdrawn
The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.
Phase 2 Withdrawn
Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
Phase 2 Withdrawn
GRN1005 for Brain Metastases From Breast or Lung Cancer
Phase 2 Withdrawn
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Phase 2 Withdrawn
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
Vigilâ„¢ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer
Phase 2 Withdrawn
Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
Phase 2 Withdrawn
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
BKM120 in Cancers With PIK3CA Activating Mutations
Phase 2 Withdrawn
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase 2 Withdrawn
A Protocol of Irinotecan for Carcinoma of the Lung
Phase 2 Withdrawn
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase 2 Withdrawn
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Phase 2 Withdrawn
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
Phase 2 Withdrawn
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
Phase 2 Withdrawn